PHILOGEN SPA (PHIL.MI) Stock Fundamental Analysis

BIT:PHIL • IT0005373789

21.1 EUR
-0.05 (-0.24%)
Last: Feb 25, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to PHIL. PHIL was compared to 77 industry peers in the Biotechnology industry. PHIL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PHIL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes PHIL very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • PHIL had positive earnings in the past year.
  • In the past year PHIL had a positive cash flow from operations.
  • In the past 5 years PHIL reported 4 times negative net income.
  • PHIL had negative operating cash flow in 4 of the past 5 years.
PHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFPHIL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • PHIL's Return On Assets of 28.81% is amongst the best of the industry. PHIL outperforms 96.10% of its industry peers.
  • PHIL's Return On Equity of 36.49% is amongst the best of the industry. PHIL outperforms 96.10% of its industry peers.
  • With an excellent Return On Invested Capital value of 21.08%, PHIL belongs to the best of the industry, outperforming 98.70% of the companies in the same industry.
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROIC 21.08%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
PHIL.MI Yearly ROA, ROE, ROICPHIL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • PHIL has a better Profit Margin (58.33%) than 96.10% of its industry peers.
  • In the last couple of years the Profit Margin of PHIL has grown nicely.
  • Looking at the Operating Margin, with a value of 49.47%, PHIL belongs to the top of the industry, outperforming 97.40% of the companies in the same industry.
  • PHIL's Gross Margin of 74.04% is fine compared to the rest of the industry. PHIL outperforms 64.94% of its industry peers.
  • PHIL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
PHIL.MI Yearly Profit, Operating, Gross MarginsPHIL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHIL is creating value.
  • Compared to 1 year ago, PHIL has about the same amount of shares outstanding.
  • Compared to 5 years ago, PHIL has less shares outstanding
  • The debt/assets ratio for PHIL has been reduced compared to a year ago.
PHIL.MI Yearly Shares OutstandingPHIL.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHIL.MI Yearly Total Debt VS Total AssetsPHIL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • PHIL has an Altman-Z score of 13.39. This indicates that PHIL is financially healthy and has little risk of bankruptcy at the moment.
  • PHIL has a better Altman-Z score (13.39) than 90.91% of its industry peers.
  • PHIL has a debt to FCF ratio of 0.31. This is a very positive value and a sign of high solvency as it would only need 0.31 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.31, PHIL belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that PHIL is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.08, PHIL is doing good in the industry, outperforming 64.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Altman-Z 13.39
ROIC/WACC2.62
WACC8.04%
PHIL.MI Yearly LT Debt VS Equity VS FCFPHIL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 5.73 indicates that PHIL has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.73, PHIL belongs to the top of the industry, outperforming 84.42% of the companies in the same industry.
  • A Quick Ratio of 5.52 indicates that PHIL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.52, PHIL belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 5.52
PHIL.MI Yearly Current Assets VS Current LiabilitesPHIL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • PHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 255.77%, which is quite impressive.
  • The Earnings Per Share has been growing by 100.72% on average over the past years. This is a very strong growth
  • Looking at the last year, PHIL shows a very strong growth in Revenue. The Revenue has grown by 3346.54%.
  • Measured over the past years, PHIL shows a very strong growth in Revenue. The Revenue has been growing by 42.46% on average per year.
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.40% on average over the next years.
  • The Revenue is expected to grow by 22.55% on average over the next years. This is a very strong growth
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue Next Year112.03%
Revenue Next 2Y-23.41%
Revenue Next 3Y-35.23%
Revenue Next 5Y22.55%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHIL.MI Yearly Revenue VS EstimatesPHIL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
PHIL.MI Yearly EPS VS EstimatesPHIL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 18.51 indicates a rather expensive valuation of PHIL.
  • 85.71% of the companies in the same industry are more expensive than PHIL, based on the Price/Earnings ratio.
  • PHIL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.05.
  • The Price/Forward Earnings ratio is 16.89, which indicates a correct valuation of PHIL.
  • PHIL's Price/Forward Earnings ratio is rather cheap when compared to the industry. PHIL is cheaper than 89.61% of the companies in the same industry.
  • PHIL's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.03.
Industry RankSector Rank
PE 18.51
Fwd PE 16.89
PHIL.MI Price Earnings VS Forward Price EarningsPHIL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 88.31% of the companies listed in the same industry.
  • 93.51% of the companies in the same industry are more expensive than PHIL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 16.76
EV/EBITDA 10.26
PHIL.MI Per share dataPHIL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PHIL has a very decent profitability rating, which may justify a higher PE ratio.
  • PHIL's earnings are expected to decrease with -63.96% in the coming years. This may justify a cheaper valuation.
PEG (NY)1.26
PEG (5Y)0.18
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHIL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHILOGEN SPA

BIT:PHIL (2/25/2026, 7:00:00 PM)

21.1

-0.05 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)03-25
Inst Owners8.98%
Inst Owner ChangeN/A
Ins Owners34.46%
Ins Owner ChangeN/A
Market Cap616.96M
Revenue(TTM)78.72M
Net Income(TTM)45.91M
Analysts80
Price Target26.52 (25.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 18.51
Fwd PE 16.89
P/S 7.84
P/FCF 16.76
P/OCF 15.6
P/B 4.9
P/tB 4.95
EV/EBITDA 10.26
EPS(TTM)1.14
EY5.4%
EPS(NY)1.25
Fwd EY5.92%
FCF(TTM)1.26
FCFY5.97%
OCF(TTM)1.35
OCFY6.41%
SpS2.69
BVpS4.3
TBVpS4.26
PEG (NY)1.26
PEG (5Y)0.18
Graham Number10.51
Profitability
Industry RankSector Rank
ROA 28.81%
ROE 36.49%
ROCE 28.1%
ROIC 21.08%
ROICexc 75.73%
ROICexgc 78.23%
OM 49.47%
PM (TTM) 58.33%
GM 74.04%
FCFM 46.77%
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.31
Debt/EBITDA 0.24
Cap/Depr 67.4%
Cap/Sales 3.47%
Interest Coverage 78.84
Cash Conversion 91.98%
Profit Quality 80.19%
Current Ratio 5.73
Quick Ratio 5.52
Altman-Z 13.39
F-Score8
WACC8.04%
ROIC/WACC2.62
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
EPS Next Y14.73%
EPS Next 2Y-53.92%
EPS Next 3Y-63.96%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
Revenue Next Year112.03%
Revenue Next 2Y-23.41%
Revenue Next 3Y-35.23%
Revenue Next 5Y22.55%
EBIT growth 1Y218.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.81%
EBIT Next 3Y-71.96%
EBIT Next 5YN/A
FCF growth 1Y1324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6769.31%
OCF growth 3YN/A
OCF growth 5Y135.99%

PHILOGEN SPA / PHIL.MI FAQ

What is the fundamental rating for PHIL stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI.


What is the valuation status for PHIL stock?

ChartMill assigns a valuation rating of 6 / 10 to PHILOGEN SPA (PHIL.MI). This can be considered as Fairly Valued.


Can you provide the profitability details for PHILOGEN SPA?

PHILOGEN SPA (PHIL.MI) has a profitability rating of 6 / 10.


What is the expected EPS growth for PHILOGEN SPA (PHIL.MI) stock?

The Earnings per Share (EPS) of PHILOGEN SPA (PHIL.MI) is expected to grow by 14.73% in the next year.